| Symbol | PLX |
|---|---|
| Name | PROTALIX BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2 UNIVERSITY PLAZA,SUITE 100, HACKENSACK, New Jersey, 07601, United States |
| Telephone | +1 201 - 696-9345 |
| Fax | — |
| — | |
| Website | https://www.protalix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001006281 |
| Description | Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The companys products also treat diseases like Fabry disease and cystic fibrosis.The companys primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement. Additional info from NASDAQ: |
(10% Negative) PROTALIX BIOTHERAPEUTICS, INC. (PLX) Reports Q3 2026 Financial Results
Read morePluxee réalise au T3 une performance conforme aux attentes et confirme ses objectifs financiers
Read morePluxee reports Q3 Fiscal 2026 performance in line with expectations and confirms its financial objectives
Read morePluxee acknowledges the filing of a claim by the Chilean Competition Authority
Read morePluxee prend connaissance de la requête déposée par la Fiscalía Nacional Económica au Chili
Read more(10% Negative) PROTALIX BIOTHERAPEUTICS, INC. (PLX) Reports Q2 2026 Financial Results
Read more